A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Inclusion criteria

• Healthy male subjects between the ages of 18 and 50 years at screening;
• Subjects with a Body Mass Index (BMI) between 18.0 (inclusive) and 28.0 kg/m2 (inclusive); and a total body weight ≥55kg (male） and 45kg (female)
• Participants who are overtly healthy as determined by medical evaluation including medical history, laboratory tests, vital signs and standard 12 lead ECGs.
• Subject is willing to participate and to Sign written informed consent form.

Exclusion criteria

• Subjects with a history of hypersensitivities to investigational products, including drug allergies (caused by aspirin, antibiotics, etc.), or a history of clinically significant hypersensitivities
• Subjects with evidence or a history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or surgery (except simple appendectomy or repair of hernia) that may influence drug absorption
• Subjects with evidence or a history of clinically significant hepatic (including carrier of viral hepatitis), renal, neurologic, immunologic, pulmonary, endocrine, hematological, neoplastic, cardiovascular or psychiatric (mood disorder, obsessive-compulsive disorder, etc.) diseases.
• Subjects with a history or current have mental disease.
• Subjects who have taken any medicine that may affect outcomes within 30 days before the first administration of the investigational product.
• Subject who have taken IBI128 in other studies.
• Subjects who have a history of acute arthiritis.
• Pregnant women or breast-feeding women or men and women who has possibility of pregnancy.
• Subjects judged not eligible for the study after reviewing the clinical laboratory results or other reasons by the investigator